| Nov 21 |
I-Mab to Participate at the Piper Sandler Healthcare Conference
|
| Nov 17 |
I-Mab Third Quarter 2024 Earnings: US$0.25 loss per share (vs US$0.57 loss in 3Q 2023)
|
| Nov 14 |
I-Mab Biopharma GAAP EPS of -$0.11 misses by $0.04
|
| Nov 14 |
I-Mab Reports Third Quarter 2024 Results
|
| Nov 6 |
I-Mab names Sean Fu as CEO
|
| Nov 6 |
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
|
| Oct 31 |
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
|
| Oct 30 |
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
|
| Oct 28 |
I-Mab to Participate at the Truist Securities BioPharma Symposium
|
| Oct 25 |
I-Mab Biopharma’s Strategic US Transition and Pipeline Focus
|
